<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479853</url>
  </required_header>
  <id_info>
    <org_study_id>SDN_2017_26</org_study_id>
    <nct_id>NCT03479853</nct_id>
  </id_info>
  <brief_title>Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE</brief_title>
  <acronym>MEIBO-ROSACEE</acronym>
  <official_title>Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to describe the clinical, meibographic and interferometric
      manifestations of phlyctenular keratitis in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are conducting a monocentric, transversal, epidemiologic study. 100
      patients should be included: 50 children suffering from ocular rosacea, and 50 children with
      no palpebral or Meibomian disease. Witnesses will be matched on the age of the cases.

      Patient and controls will undergo a classic ophthalmologic examination with visual acuity
      measurement and slit lamp examination of both eyes and eyelids. Then, the child will go
      through a meibographic and interferometric evaluation of his two inferior eyelids. This
      evaluation is made by an optometrist with the Lipiview device, and lasts a few minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical severity</measure>
    <time_frame>Day of inclusion</time_frame>
    <description>Clinical severity is determined with a composite score, by the presence of chalazia, corneal lesions, neovascularization, phlyctena, loss of vision, superficial keratitis, anterior and posterior keratitis, meibomitis, palpebral margin keratinization, lagophthalmos, long term use of azithromycin treatment, treatment by ciclosporin eyedrops, intense cutaneous or ocular symptoms, long time evolution of the disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Meibographic severity</measure>
    <time_frame>Day of inclusion</time_frame>
    <description>The meibographic severity is determined by the level of Meibomian gland atrophy, data obtained with the Lipiview</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interferometric severity</measure>
    <time_frame>Day of inclusion</time_frame>
    <description>The interferometric severity is evaluated by the thickness of the lipid layer tear film, data obtained with the Lipiview</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of abortive blinks</measure>
    <time_frame>Day of inclusion</time_frame>
    <description>Number of abortive blinks during the Lipiview exam</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ocular Rosacea</condition>
  <condition>Keratoconjunctivitis</condition>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Cases : suffering from ocular or oculo-cutaneous rosacea</arm_group_label>
    <description>Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Witnesses</arm_group_label>
    <description>Without any present or past palpebral meibomian Gland Dysfunction
Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)</intervention_name>
    <description>Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.</description>
    <arm_group_label>Cases : suffering from ocular or oculo-cutaneous rosacea</arm_group_label>
    <arm_group_label>Witnesses</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children aged between 2 and 16 : Cases, suffering from ocular or oculo-cutaneous rosacea
        and Witnesses without any present or past palpebral or meibomian disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recruited from a specialized ophthalmologic consultation Rothschild Ophthalmologic
             Foundation, Paris, France.

          -  Cases : suffering from ocular or oculo-cutaneous rosacea

          -  Witnesses : without any present or past palpebral or meibomian disease

        Exclusion Criteria:

          -  Unable to achieve the meibographic and interferometric examination (Lipiview)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge DOAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence SALOMON, MD</last_name>
    <phone>0148036431</phone>
    <phone_ext>+33</phone_ext>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondation Ophtalmologique A. de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge DOAN, MD</last_name>
      <email>serge.doan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tiphanie AUDELAN</last_name>
      <email>tiphanie.audelan@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Rosacea</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <keyword>Meibomian Gland</keyword>
  <keyword>Interferometry</keyword>
  <keyword>Child</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Keratitis</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

